Peer-reviewed veterinary case report
High fibroblast growth factor 23 in dogs with chronic kidney disease
By Dittmer, Keren E et al.·Published in Research in veterinary science·2017·Institute of Veterinary·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Serum fibroblast growth factor 23 concentrations in dogs with chronic kidney disease.
- Species:
- dog
Plain-English summary
A group of dogs with chronic kidney disease (CKD) showed significantly higher levels of a protein called fibroblast growth factor 23 (FGF23) compared to healthy dogs. Symptoms of CKD in these dogs included increased thirst and urination, along with elevated waste products in the blood. The study found that the higher FGF23 levels were linked to increased phosphorus levels in the blood, which could help in developing new treatments for managing CKD. Understanding these connections may lead to better ways to control kidney disease in dogs.
People also search for: dog chronic kidney disease symptoms · high phosphorus in dogs · treatment for dog kidney disease
Abstract
The aim of this study was to determine if serum fibroblast growth factor (FGF23) concentrations were increased in dogs with chronic kidney disease (CKD). Serum samples submitted to a commercial laboratory were collected over a 15-month period, 14 samples were from dogs with a history of polyuria/polydipsia, azotaemia and low urine specific gravity, 20 samples were from non-azotaemic dogs. Serum FGF23, parathyroid hormone, total calcium and phosphorus, urea and creatinine were measured. Mann-Whitney test was used to determine differences between non-azotaemic and CKD groups; a one-way ANOVA with Tukey pairwise comparisons was used to determine any differences between International Renal Interest Society stages; and regression models were used to determine predictors of International Renal Interest Society stage, serum phosphorus and FGF23 concentrations. The median serum FGF23 concentration of dogs with CKD was 5194.6pg/mL, which was significantly greater (P<0.001) than the median serum FGF23 concentration of non-azotaemic dogs (259.2pg/mL). Log serum FGF23 and age were significantly associated with IRIS stage (P=0.027 and P=0.032 respectively), while log serum phosphorus concentration (P<0.001) was significantly associated with log serum FGF23 concentration. In summary, serum FGF23 concentration is increased in dogs with CKD, and is associated with serum phosphorus concentration. This phosphatonin pathway may be a useful target for the development of future treatments to control plasma phosphorus concentrations in chronic kidney disease.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28667925/